Risk Assessment for Hepatobiliary Toxicity Liabilities in Drug Development

Area of Science:

• Toxicologic Pathology
• Drug Safety Evaluation

Background:

• Hepatobiliary toxicity risk assessment is a complex challenge in toxicologic pathology.
• Animal models often show limited predictivity for human hepatic effects.
• Each hepatotoxicity case requires a unique, data-driven assessment.

Purpose of the Study:

• To outline a holistic and integrated approach for assessing hepatobiliary toxicity risks.
• To emphasize the importance of diverse data integration in risk assessment.
• To highlight the challenges and rewards of evaluating liver toxicity.

Main Methods:

• Integrating data from nonclinical toxicology studies.
• Incorporating Absorption, Distribution, Metabolism, and Excretion (ADME) data, including transporter information and exposure margins.
• Utilizing in silico predictions, in vitro hepatocyte data, biomarkers, and target expression/function data.
• Considering species specificity and clinical data on patient populations.

Main Results:

• A multi-faceted approach is necessary for accurate hepatotoxicity risk assessment.
• The integration of diverse data sources improves the predictivity of potential human hepatic effects.
• Understanding patient population liver disease status is paramount.

Conclusions:

• Accurate hepatobiliary risk assessment requires a holistic integration of diverse data.
• Close collaboration with clinical colleagues is essential for evaluating patient-specific risks.
• The established translatability of nonclinical hepatic events to humans supports this integrated approach.